04 Apr 2023
A joint safety alert has been issued from the British Menopause Society, Faculty of Sexual & Reproductive Healthcare, Royal College of General Practitioners, Royal College of Obstetricians & Gynaecologists, Society for Endocrinology and the Royal College of Nursing Women’s Health Forum.
This safety alert has been produced in response to questions raised in relation to appropriate doses of oestrogen and progestogen provided to women experiencing symptoms of menopause.
Current National Institute for Health and Care Excellence (NICE), MHRA and national and international guidance recommends the lowest effective dose to control symptoms, but an increasing numbers of women are being initiated on high doses of oestrogen which exceed the product licenses, not in line with any clinical guidelines.
Read the alert in full.
Study links premature ovarian insufficiency (POI) to risk of mortality
17 May 2024
Cardiovascular disease mortality associated with low testosterone in men
17 May 2024
People with obesity using semaglutide see cardiovascular improvements
17 May 2024
Men with obesity lose more weight with cash incentives, research says
17 May 2024
Research Assistant in Endocrinology (University of Sheffield)
14 May 2024